SYSFOL EYE DROPS- polyethylene glycol 400, propylene glycol liquid
Unimed Pharmaceuticals, Inc.

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Drug Facts

Polyethylene Glycol 400, Propylene Glycol

boric acid, hypromellose, potassium chloride, purified water, sodium chloride, sodium hyaluronate, sodium, hydroxide

for use as a protectant against further irritation or to relieve dryness of the eye

keep out of reach of the children

Instill 1 or 2 drops in the affectd eye(s) as needed

For external use only
When using this product
■ do not touch tip of container to any surface to avoid contamination
■ replace cap after each use

■ avoid direct sunlight

external use only



SYSFOL EYE DROPS

polyethylene glycol 400, propylene glycol liquid

Product Information			
Product Type	HUMAN OTC DRUG	**Item Code (Source)**	NDC:73669-013
Route of Administration	OPHTHALMIC		

Active Ingredient/Active Moiety		
Ingredient Name	**Basis of Strength**	**Strength**
POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ) (POLYETHYLENE GLYCOL 400 - UNII:B697894SGQ)	POLYETHYLENE GLYCOL 400	0.4 g in 100 mL
PROPYLENE GLYCOL (UNII: 6DC9Q167V3) (PROPYLENE GLYCOL - UNII:6DC9Q167V3)	PROPYLENE GLYCOL	0.3 g in 100 mL

Inactive Ingredients

Ingredient Name	Strength
WATER (UNII: 059QF0KO0R)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:73669-013-02	30 in 1 BOX	04/20/2023	
1	NDC:73669-013-01	0.4 mL in 1 CONTAINER; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
unapproved drug other		04/20/2023	

Labeler - Unimed Pharmaceuticals, Inc. (689852052)

Registrant - Unimed Pharmaceuticals, Inc. (689852052)

Establishment

Name	Address	ID/FEI	Business Operations
Unimed Pharmaceuticals, Inc.		689852052	label(73669-013) , manufacture(73669-013) , pack(73669-013)

Revised: 5/2023 Unimed Pharmaceuticals, Inc.